GSK Oncology Pipeline Expansion Means Healthy Phase III Program In ’06

GlaxoSmithKline's strategy of building its oncology business is paying off with a range of new chemical entities entering Phase III development within the next year for cancer-related indications, executives said during an oncology R&D update in New York